AI Terminal
FUTURA MEDICAL PLC
Regulatory Filings • Dec 2, 2024
7656_rns_2024-12-02_c9319aa6-51a2-4f7d-ae90-53a9c1477538.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2516O
Futura Medical PLC
02 December 2024
2 December 2024
Futura Medical PLC
Block Listing Six Monthly Return
Futura Medical plc (AIM: FUM), a developer of innovative sexual health products, including lead product Eroxon, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Date: 2 December 2024
| Name of applicant: | Futura Medical Plc | |||
| Name of scheme(s): | Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme LTIP Scheme |
|||
| Period of return: | From: | 1 June 2024 | To: | 30 November 2024 |
| Balance of unallotted securities under scheme(s) from previous return: | 20,782,665 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | USOS: nil USIS: nil EMI: nil LTIP: nil |
|||
| Less: Number of securities issued/allotted under scheme(s) during period: | USOS: 250,000 USIS: nil EMI: 250,000 LTIP: 1,754,120 |
|||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 18,528,545 | |||
| Number and class of securities originally admitted and the date of admission | USOS Total: 3,882,912 814,424 25 May 2011 1,202,280 8 October 2013 1,466,208 25 May 2017 400,000 30 May 2018 USIS Total: 425,000 425,000 30 November 2018 EMI Total: 8,112,088 1,520,576 25 May 2011 1,467,720 8 October 2013 1,893,792 25 May 2017 790,000 30 May 2018 1,340,000 30 November 2018 1,100,000 2 February 2023 LTIP Total: 15,035,617 4,444,942 2 February 2023 10,590,675 3 November 2023 |
|||
Contacts:
| Futura Medical plc | James Barder Chief Executive Officer Angela Hildreth Finance Director and COO |
[email protected] +44 (0)1483 685 670 www.futuramedical.com |
| Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) |
+44 (0)20 3100 2000 |
| Stifel Nicolaus Europe Limited Joint Broker |
Alan Selby Ben Maddison |
+44 (0)207 710 7600 |
| Alma Strategic Communications | Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock |
+44 (0)20 3405 0205 [email protected] |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.
ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRBLBFTMTITBTI